PEOPLE - Bioject (US) makes appointment:
This article was originally published in Clinica
Developer of needle-free drug delivery systems Bioject (Bedminster, New Jersey) has appointed Eric Mishkin as senior vice-president and chief scientific officer. Dr Mishkin, who has over 25 years of experience in immunology research and microbiology, most recenly served as director of immunology research at Wyeth-Ayerst. It has also announced the appointment of Chris Pugh, who has over 10 years of product and business development experience, as director of business development.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.